Bioventus Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$605Mnext fiscal year
FY EPS (est.)
$0.78next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Worldwide Net Sales Quarterly132.1MTarget: 600000000 to 610000000
Adjusted EBITDA Margin Quarterly18.0%
Non-GAAP Adjusted EPS Quarterly0.2Target: 0.75 to 0.79
Cash from Operations Quarterly8.9MTarget: 84000000 to 89000000
Watch Items
- CMS Reimbursement Cuts for Non-Invasive Bone Growth StimulatorsTrigger: Top-line headwind exceeding $2-3 million in FY26Action: Monitor commercial execution in the U.S. bone growth stimulation business and assess mitigation from high-growth segments like PNS and PRP.
- Debt Reduction and Leverage RatioTrigger: Debt-to-equity ratio exceeding 120%Action: Track the acceleration of cash generation and debt paydown progress to reduce interest expenses and improve capital flexibility.
Research as of 19 Jun 2026